{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:39:23Z","timestamp":1791383963954,"version":"4.3.3"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Narcolepsy, a rare neurological disorder believed to have an autoimmune etiology, necessitates lifelong management. This study aimed to provide evidence supporting the safety of pharmacological treatment for narcolepsy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Five-year data on pitolisant, sodium oxybate, solriamfetol, and modafinil were extracted from the FDA Adverse Event Reporting System (FAERS) self-reporting database for the period spanning from 2019 to 2023. Various statistical methods, including the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network analysis (BCPNN), and multi-item gamma Poisson shrinker (MGPS), were employed to quantify the signals. Finally, a comparative analysis was conducted between demographic data, outcomes, and inherent associations among the medications and the signals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After data analysis, we obtained 50 signals (a cumulative count of 762 cases) for pitolisant, 640 signals (corresponding to 46,962 cases) for sodium oxybate, 40 signals (equivalent to 1,228 cases) for solriamfetol, and finally, 72 signals (representing 632 cases) for modafinil. The majority of these patients were female. Psychiatric and nervous system disorders were identified as the predominant adverse drug events (ADEs). For sodium oxybate, it is crucial to consider psychiatric disorders (such as suicidal ideation), respiratory disorders (including sleep apnea syndrome and respiratory depression), and signs of pregnancy and congenital familial diseases. For solriamfetol, noteworthy new ADEs include drug inefficacy, suicidal ideation, restless legs syndrome, and somnambulism. Furthermore, a relationship has been observed between modafinil use and restricted fetal growth, spontaneous abortion, cognitive disorders, and drug inefficacy and abuse.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The majority of observed adverse reactions in this study were consistent with those listed in the product instructions. However, potential novel or notable ADE signals were identified through real-world pharmacovigilance analysis. It is anticipated that this paper will offer additional information regarding safe and rational medication for narcolepsy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1415918","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T04:39:14Z","timestamp":1731299954000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the FAERS database"],"prefix":"10.3389","volume":"15","author":[{"given":"Xiaodan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bangtian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.sleep.2020.09.017","article-title":"The sodium in sodium oxybate: is there cause for concern?","volume":"75","author":"Avidan","year":"2020","journal-title":"Sleep. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41582-019-0226-9","article-title":"Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment","volume":"15","author":"Bassetti","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e13387","DOI":"10.1111\/jsr.13387","article-title":"European guideline and expert statements on the management of narcolepsy in adults and children","volume":"30","author":"Bassetti","year":"2021","journal-title":"J. Sleep. Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jama.2020.9840","article-title":"Incidence of malformations after early pregnancy exposure to modafinil in Sweden and Norway","volume":"324","author":"Cesta","year":"2020","journal-title":"JAMA"},{"key":"B5","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1089\/cap.2012.0130","article-title":"Sodium oxybate-induced psychosis and suicide attempt in an 18-year-old girl","volume":"23","author":"Chien","year":"2013","journal-title":"J. Child. Adolesc. Psychopharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jama.2019.20008","article-title":"First-trimester pregnancy exposure to modafinil and risk of congenital malformations","volume":"323","author":"Damkier","year":"2020","journal-title":"JAMA"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/s1474-4422(13)70225-4","article-title":"Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial","volume":"12","author":"Dauvilliers","year":"2013","journal-title":"Lancet Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S1474-4422(23)00036-4","article-title":"Safety and efficacy of pitolisant in children aged 6 years or older with narcolepsy with or without cataplexy: a double-blind, randomised, placebo-controlled trial","volume":"22","author":"Dauvilliers","year":"2023","journal-title":"Lancet Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1212\/wnl.57.11.2029","article-title":"Age at onset of narcolepsy in two large populations of patients in France and Quebec","volume":"57","author":"Dauvilliers","year":"2001","journal-title":"Neurology"},{"key":"B10","unstructured":"Drugs@FDA: FDA-approved drugs2024"},{"key":"B11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.sleep.2011.06.020","article-title":"TCRA, P2RY11, and CPT1B\/CHKB associations in Chinese narcolepsy","volume":"13","author":"Han","year":"2012","journal-title":"Sleep. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s40263-023-01040-5","article-title":"Solriamfetol: a review in excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnoea","volume":"37","author":"Hoy","year":"2023","journal-title":"CNS Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"E17","DOI":"10.1503\/cmaj.230650","article-title":"Narcolepsy","volume":"196","author":"Humphreys","year":"2024","journal-title":"CMAJ"},{"key":"B14","doi-asserted-by":"publisher","first-page":"zsae038","DOI":"10.1093\/sleep\/zsae038","article-title":"Medication-induced central sleep apnea: a unifying concept","volume":"47","author":"Javaheri","year":"2024","journal-title":"Sleep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamainternmed.2020.4009","article-title":"Pregnancy and fetal outcomes following exposure to modafinil and armodafinil during pregnancy","volume":"181","author":"Kaplan","year":"2021","journal-title":"JAMA Intern Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/jsr.12374","article-title":"The European narcolepsy network (EU-NN) database","volume":"25","author":"Khatami","year":"2016","journal-title":"J. Sleep. Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"16100","DOI":"10.1038\/nrdp.2016.100","article-title":"Narcolepsy","volume":"3","author":"Kornum","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jpsychires.2022.08.018","article-title":"Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depression","volume":"155","author":"Krystal","year":"2022","journal-title":"J. Psychiatr. Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40263-020-00703-x","article-title":"Pitolisant: a review in narcolepsy with or without cataplexy","volume":"34","author":"Lamb","year":"2020","journal-title":"CNS Drugs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41583-018-0097-x","article-title":"The neurobiological basis of narcolepsy","volume":"20","author":"Mahoney","year":"2019","journal-title":"Nat. Rev. Neurosci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/j.1553-2712.2002.tb02154.x","article-title":"Gamma hydroxybutyric acid (GHB) intoxication","volume":"9","author":"Mason","year":"2002","journal-title":"Acad. Emerg. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1093\/sleep\/30.12.1705","article-title":"Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin","volume":"30","author":"Morgenthaler","year":"2007","journal-title":"Sleep"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1212\/wnl.58.12.1826","article-title":"Prevalence of narcolepsy symptomatology and diagnosis in the European general population","volume":"58","author":"Ohayon","year":"2002","journal-title":"Neurology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"352r e326","DOI":"10.1176\/jnp.2010.22.3.352.e26","article-title":"Suicidal ideation secondary to sodium oxybate","volume":"22","author":"Ortega-Albas","year":"2010","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/S1474-4422(14)70075-4","article-title":"Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination","volume":"13","author":"Partinen","year":"2014","journal-title":"Lancet Neurol."},{"key":"B26","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/978-1-4939-6578-6_28","article-title":"Epidemiology: principles and application in sleep medicine","volume-title":"Sleep disorders medicine: basic science, technical considerations and clinical aspects","author":"Partinen","year":"2017"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1016\/j.ijmedinf.2009.01.001","article-title":"Influence of the MedDRA hierarchy on pharmacovigilance data mining results","volume":"78","author":"Pearson","year":"2009","journal-title":"Int. J. Med. Inf."},{"key":"B28","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/j.1600-0773.1980.tb01569.x","article-title":"Central cardiovascular effects of gamma-hydroxybutyric acid: interactions with noradrenaline, serotonin, dopamine and acetylcholine transmission","volume":"47","author":"Persson","year":"1980","journal-title":"Acta Pharmacol. Toxicol. (Copenh)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1177\/1060028020915537","article-title":"Solriamfetol for excessive sleepiness in narcolepsy and obstructive sleep apnea","volume":"54","author":"Powell","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2165\/00023210-200721040-00007","article-title":"Sodium oxybate: a review of its use in the management of narcolepsy","volume":"21","author":"Robinson","year":"2007","journal-title":"CNS Drugs"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1056\/NEJMra1500587","article-title":"Narcolepsy","volume":"373","author":"Scammell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2147\/NSS.S412793","article-title":"Long-term treatment of narcolepsy and idiopathic hypersomnia with low-sodium oxybate","volume":"15","author":"Schneider","year":"2023","journal-title":"Nat. Sci. Sleep."},{"key":"B33","doi-asserted-by":"publisher","first-page":"990241","DOI":"10.3389\/fphar.2022.990241","article-title":"Fluoroquinolone-associated suspected tendonitis and tendon rupture: a pharmacovigilance analysis from 2016 to 2021 based on the FAERS database","volume":"13","author":"Shu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s40265-016-0620-1","article-title":"Pitolisant: first global approval","volume":"76","author":"Syed","year":"2016","journal-title":"Drugs"},{"key":"B35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40263-019-00689-1","article-title":"Recently approved and upcoming treatments for narcolepsy","volume":"34","author":"Thorpy","year":"2020","journal-title":"CNS Drugs"},{"key":"B36","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.sleep.2014.01.015","article-title":"Delayed diagnosis of narcolepsy: characterization and impact","volume":"15","author":"Thorpy","year":"2014","journal-title":"Sleep. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"851246","DOI":"10.3389\/fphar.2022.851246","article-title":"Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS","volume":"13","author":"Tian","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B38","unstructured":"FDA adverse event reporting system (FAERS) quarterly data extract files2024"},{"key":"B39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"Van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B40","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.sleep.2023.01.022","article-title":"Solriamfetol real world experience study (SURWEY): initiation, titration, safety, effectiveness, and experience during follow-up for patients with narcolepsy from Germany","volume":"103","author":"Winter","year":"2023","journal-title":"Sleep. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.sleep.2013.12.012","article-title":"Symptoms and occurrences of narcolepsy: a retrospective study of 162 patients during a 10-year period in eastern China","volume":"15","author":"Wu","year":"2014","journal-title":"Sleep. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/17512433.2019.1632705","article-title":"Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy","volume":"12","author":"Yang","year":"2019","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.2147\/nss.s359980","article-title":"Idling for decades: a European study on risk factors associated with the delay before a narcolepsy diagnosis","volume":"14","author":"Zhang","year":"2022","journal-title":"Nat. Sci. Sleep."},{"key":"B44","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/cpdd.867","article-title":"A randomized, double-blind, placebo- and positive-controlled, 4-period crossover study of the effects of solriamfetol on QTcF intervals in healthy participants","volume":"10","author":"Zomorodi","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1415918\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T04:39:18Z","timestamp":1731299958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1415918\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":44,"alternative-id":["10.3389\/fphar.2024.1415918"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1415918","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,11]]},"article-number":"1415918"}}